SCHEMBL6487186

SCHEMBL6487186

O=C(O)/C=C/C(=O)Nc1n[nH]c2ccc(Br)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.51
AURKA O14965 6/20 0.48
GSK3B P49841 2/20 0.47
FADS1 O60427 1/20 0.44
PDPK1 O15530 1/20 0.44
JAK2 O60674 1/20 0.44
AURKB Q96GD4 2/20 0.43
DCLK1 O15075 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43
CSF1R P07333 1/20 0.43
FER P16591 1/20 0.43
CDK2 P24941 1/20 0.43
MARK3 P27448 1/20 0.43
FLT4 P35916 1/20 0.43
FLT3 P36888 1/20 0.43
MAPK9 P45984 1/20 0.43
CSNK1D P48730 1/20 0.43
CLK2 P49760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487193 1.00 DYRK1A (0.51) DYRK1AAURKAGSK3BFADS1PDPK1
SCHEMBL15484549 1.00 DYRK1A (0.51) DYRK1AAURKAGSK3BFADS1PDPK1
Maleic Acid SCHEMBL11766203 0.79 JAK2 (0.73) DYRK1APDPK1JAK2AURKBDCLK1
Fumaric Acid SCHEMBL11766217 0.79 JAK2 (0.73) DYRK1APDPK1JAK2AURKBDCLK1
SCHEMBL15484454 0.76 GSK3B (0.62) DYRK1AAURKAGSK3BGSK3A
SCHEMBL1461613 0.76 GSK3B (0.62) DYRK1AAURKAGSK3BGSK3A
SCHEMBL1461615 0.76 GSK3B (0.62) DYRK1AAURKAGSK3BGSK3A
SCHEMBL6478923 0.76 DYRK1A (0.69) DYRK1AGSK3BPDPK1JAK2EGFR
SCHEMBL15484452 0.76 DYRK1A (0.69) DYRK1AGSK3BPDPK1JAK2EGFR
SCHEMBL6478928 0.76 DYRK1A (0.69) DYRK1AGSK3BPDPK1JAK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487804-B1 AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2014-02-26 EP claimed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US claimed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 US claimed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US disclosed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof CYP2C8, NR0B2, NR2C2 DYRK1A 1638/4885AURKA 3296/4885GSK3B 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.